Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Korean J Intern Med. 2021;36(4):975-984. Published online 2021 Apr 6 DOI: https://doi.org/10.3904/kjim.2020.178
Citations to this article as recorded by 
Spontaneous regression of recurrent pulmonary large cell neuroendocrine carcinoma with alteration of PD‐L1 expression after surgical resection: A case report
Green Hong, Chaeuk Chung, Dongil Park, Song‐I Lee, Jeong Eun Lee, Da Hyun Kang
Thoracic Cancer.2024; 15(3): 266. CrossRef
Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma: Systematic Review of International Clinical Trials
Christian Bolenz, Frank Kunath, Friedemann Zengerling, Felix Wezel, Stefanie Schmidt, Arndt Hartmann, Markus Eckstein
Urologia Internationalis.2023; 107(5): 480. CrossRef
Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise
Brian Healey Bird, Ken Nally, Karine Ronan, Gerard Clarke, Sylvie Amu, Ana S. Almeida, Richard Flavin, Stephen Finn
Diagnostics.2022; 12(1): 124. CrossRef
The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure
Hiromitsu Suganuma, Sojiro Kusumoto, Ryo Manabe, Yasunari Kishino, Tetsuya Endo, Koichi Ando, Hiroo Ishida, Atsushi Horiike, Akihiko Tanaka, Hidefumi Takei, Toshiko Yamochi, Takuya Tsunoda, Hironori Sagara
The Showa University Journal of Medical Sciences.2022; 34(2): 64. CrossRef
Advances in Neoadjuvant and Adjuvant Immunotherapy and Targeted Therapy for Resectable NSCLC (CME article)
Fares Alsawah, Dipesh Uprety
International Journal of Cancer Care and Delivery.2022;[Epub] CrossRef